AstraZeneca PLC (AZN)vsLive Nation Entertainment Inc (LYV)
AZN
AstraZeneca PLC
$182.85
+0.18%
HEALTHCARE · Cap: $286.68B
LYV
Live Nation Entertainment Inc
$163.28
-1.49%
COMMUNICATION SERVICES · Cap: $38.57B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 136% more annual revenue ($60.44B vs $25.61B). AZN leads profitability with a 17.2% profit margin vs 0.3%. AZN appears more attractively valued with a PEG of 1.52. AZN earns a higher WallStSmart Score of 62/100 (C+).
AZN
Buy62
out of 100
Grade: C+
LYV
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+6.6%
Fair Value
$220.34
Current Price
$182.85
$37.49 discount
Margin of Safety
+12.2%
Fair Value
$172.04
Current Price
$163.28
$8.76 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 24 in profit
Strong operational efficiency at 28.2%
Generating 1.8B in free cash flow
Generating 2.0B in free cash flow
Areas to Watch
Expensive relative to growth rate
Moderate valuation
Distress zone — elevated risk
0.3% margin — thin
Weak financial health signals
Expensive relative to growth rate
Trading at 140.8x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 28.2%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : LYV
The strongest argument for LYV centers on Free Cash Flow. Revenue growth of 12.2% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Altman Z-Score.
Bear Case : LYV
The primary concerns for LYV are Profit Margin, Piotroski F-Score, PEG Ratio. Thin 0.3% margins leave little buffer for downturns.
Key Dynamics to Monitor
AZN profiles as a mature stock while LYV is a value play — different risk/reward profiles.
LYV carries more volatility with a beta of 1.11 — expect wider price swings.
AZN is growing revenue faster at 12.5% — sustainability is the question.
LYV generates stronger free cash flow (2.0B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (62/100 vs 42/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Live Nation Entertainment Inc
COMMUNICATION SERVICES · ENTERTAINMENT · USA
Live Nation Entertainment, Inc is an American global entertainment company, founded in 2010, following the merger of Live Nation and Ticketmaster. The company promotes, operates, and manages ticket sales for live entertainment in the United States and internationally. It also owns and operates entertainment venues, and manages the careers of music artists.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?